DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer
Status:
Completed
Trial end date:
2021-02-25
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to investigate if maintenance DCVAC/OvCa after second-line
chemotherapy of carboplatin/gemcitabine or carboplatin/paclitaxel improves efficacy outcomes
in women with FIGO stage III and IV epithelial ovarian carcinoma who experienced relapse more
than 6 months after complete remission of first line platinum-based chemotherapy (platinum
sensitive ovarian cancer)